Literature DB >> 15876154

Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.

Rue-Tsuan Liu1, Fong-Fu Chou, Chih-Hui Wang, Chang-Lin Lin, Fang-Ping Chao, Jui-Chen Chung, Chao-Cheng Huang, Pei-Wen Wang, Jiin-Tsuey Cheng.   

Abstract

Somatic rearrangement of the tyrosine kinase receptor RET is restricted to papillary thyroid carcinoma (PTC). The prevalence of RET/PTC1, RET/PTC2, and RET/PTC3 has been found to vary between 0% and 20% in most series of sporadic (nonradiation-induced) PTCs analyzed by type-specific reverse transcription-polymerase chain reaction (RT-PCR) alone. However, high prevalence reported from Taiwan (6 out of 11, 55%) indicates RET rearrangement is an important genetic lesion underlying the development of PTC in Taiwan. Because the high prevalence of RET rearrangements in Chinese patients was particularly striking, we were prompted to reexamine chimeric transcripts of RET/PTC1, RET/PTC2, and RET/PTC3 using the same experimental designs in a larger number of cases in the same population. RT-PCR was performed to amplify fusion products of RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET from frozen tissue of 105 sporadic PTCs. RT-PCR was also performed with two different primer sets for RET/PTC1, RET/PTC2, and RET/PTC3 followed by Southern hybridization in the first 62 tumors. In our study, RET/PTC1, RET/PTC2, and RET/PTC3 oncogenes were found in only 7 of 105 (7%) sporadic PTCs. Of these tumors, 3 involved RET/PTC1 and 4 involved RET/PTC3. No RET/PTC2 rearrangements were observed. In the first 62 tumor samples, another two different primer sets for each rearrangement also gave concordant results. Furthermore, application of Southern hybridization in these 62 PTCs did not identify additional tumor harboring RET chimeric transcripts. We identified one tumor as having an ELKS-RET rearrangement (1 of 105, 1%). In conclusion, we detected RET rearrangements in 8 of 105 (8%) sporadic PTCs in Taiwan, a much lower prevalence than previously reported for this population but comparable to those reported in other nations using similar methodology. RET chimeric oncogenes only account for a small fraction of PTCs in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876154     DOI: 10.1089/thy.2005.15.326

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

2.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.

Authors:  Alessio Amatu; Andrea Sartore-Bianchi; Salvatore Siena
Journal:  ESMO Open       Date:  2016-03-18

4.  Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations.

Authors:  Jiang Chang; Wenle Tan; Zhiqiang Ling; Ruibin Xi; Mingming Shao; Mengjie Chen; Yingying Luo; Yanjie Zhao; Yun Liu; Xiancong Huang; Yuchao Xia; Jinlin Hu; Joel S Parker; David Marron; Qionghua Cui; Linna Peng; Jiahui Chu; Hongmin Li; Zhongli Du; Yaling Han; Wen Tan; Zhihua Liu; Qimin Zhan; Yun Li; Weimin Mao; Chen Wu; Dongxin Lin
Journal:  Nat Commun       Date:  2017-05-26       Impact factor: 14.919

5.  Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence.

Authors:  Biagio Ricciuti; Carlo Genova; Lucio Crinò; Massimo Libra; Giulia Costanza Leonardi
Journal:  Onco Targets Ther       Date:  2019-04-30       Impact factor: 4.147

Review 6.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.

Authors:  Massimo Santoro; Marialuisa Moccia; Giorgia Federico; Francesca Carlomagno
Journal:  Genes (Basel)       Date:  2020-04-15       Impact factor: 4.096

7.  Development of an RNA sequencing panel to detect gene fusions in thyroid cancer.

Authors:  Dongmoung Kim; Seung-Hyun Jung; Yeun-Jun Chung
Journal:  Genomics Inform       Date:  2021-12-31

8.  Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.

Authors:  Hui-qin Guo; Huan Zhao; Zhi-hui Zhang; Yan-li Zhu; Ting Xiao; Qin-jing Pan
Journal:  Dis Markers       Date:  2014-01-29       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.